Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis

Advances in Therapy

Volumn 31, Issue 9, 2014, Pages 915-931

  Marziniak, Martin ^a   Meuth, Sven ^b  

^a KLINIKUM MÜNCHEN OST   (Germany)

^b Institut fur Physiologie   (Germany)

Author keywords

Autoinjector; Clinical trial; Clinically isolated syndrome; Disease modifying therapy; Multiple sclerosis; Neurology; Relapsing remitting; Safety; Secondary progressive; Tolerability

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO; TERIFLUNOMIDE; BETA INTERFERON;

AUTOINJECTOR; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; INJECTION SITE PAIN; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RELAPSE; REVIEW; ULCER; SUBCUTANEOUS DRUG ADMINISTRATION;

DISEASE PROGRESSION; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON BETA-1B; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 84919712350     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0149-1     Document Type: Review

References (74)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17.
2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.
3. Lublin F. History of modern multiple sclerosis therapy. J Neurol. 2005;252(Suppl 3):iii3–iii9.
4. Schwid SR, Panitch HS. Full results of the evidence of interferon dose-response-European North American comparative efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29:2031–48.
5. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389–97.
6. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242–9.
7. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898–904.
8. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491–7.
9. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56:1496–504.
10. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679–87.
11. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576–82.
12. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503–11.
13. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis. Ann Neurol. 2013;73:705–13.
14. Meuth SG, Gobel K, Wiendl H. Immune therapy of multiple sclerosis––future strategies. Curr Pharm Des. 2012;18:4489–97.
15. Burks J. Interferon-beta1b for multiple sclerosis. Expert Rev Neurother. 2005;5:153–64.
16. Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2009;10:291–309.
17. Brochet B, Lemaire G, Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Rev Neurol (Paris). 2006;162:735–40.
18. Girouard N, Theoret G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs. 2008;30:18–25.
19. Lugaresi A, Durastanti V, Gasperini C, et al. Safety and tolerability in relapsing–remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Clin Neuropharmacol. 2008;31:167–72.
20. Boeru G, Milanov I, De Robertis F, et al. ExtaviJect(R) 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Med Devices (Auckl). 2013;6:175–84.
21. ® devices. Pragmat Obs Res. 2013;4:19–26.
22. Department of Health and Human Services. Interferon beta-1b––approval Letter, 23 July 1993. http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/103471s0000_APPROV.pdf. Accessed 27 June 2014.
23. European Medicines Agency. Betaferon––European Public Assessment Report: summary for the public, May 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000081/WC500053086.pdf. Accessed 27 June 2014.
24. Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing–remitting MS. Neurology. 2010;74:1877–85.
25. ®––summary of product characteristics, 20 May 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000933/WC500034701.pdf. Accessed 27 June 2014.
26. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.
27. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–31.
28. Edan G, Kappos L, Montalban X, et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2013. doi:10.1136/jnnp-2013-306222 (Epub ahead of print).
29. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–61.
30. Paty DW, Li DK. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:662–7.
31. Goodin DS, Traboulsee A, Knappertz V, 16-year Long Term Follow-up Study Investigators, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:282–7.
32. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology. 2012;78:1315–22.
33. Torkildsen GN, Lie SA, Aarseth JH, Nyland H, Myhr KM. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler. 2008;14:1191–8.
34. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010;81:907–12.
35. Goodin DS, Ebers GC, Cutter G, et al. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNbeta-1b study. BMJ Open. 2012;2:e001972. doi:10.1136/bmjopen-2012-001972.
36. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788–95.
37. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology. 2001;57:1969–75.
38. Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol. 1999;46:850–9.
39. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63:1779–87.
40. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453–60.
41. Koch-Henriksen N, Sorensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing–remitting multiple sclerosis. Neurology. 2006;66:1056–60.
42. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing–remitting multiple sclerosis. Acta Neurol Scand. 2006;113:283–7.
43. O’Connor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889–97.
44. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72:1976–83.
45. Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013;6:CD008933.
46. Filippi M, Rocca MA, Camesasca F, et al. Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011;76:1222–8.
47. Cadavid D, Cheriyan J, Skurnick J, et al. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry. 2009;80:1337–43.
48. ® prescribing information. 2012. https://www.pharma.us.novartis.com/product/pi/pdf/extavia.pdf. Accessed 27 June 2014.
49. Creeke PI, Farrell RA. Clinical testing for neutralizing antibodies to interferon-beta in multiple sclerosis. Ther Adv Neurol Disord. 2013;6:3–17.
50. Goodin DS, Hartung HP, O’Connor P, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012;18:181–95.
51. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225–40.
52. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60.
53. ® prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf. Accessed 27 June 2014.
54. Oh J, O’Connor PW. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177–90.
55. ® prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf. Accessed 27 June 2014.
56. Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014;30:251–62.
57. ®––summary of opinion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf. Accessed 27 June 2014.
58. Maddison P, Kiely P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford). 2005;44:280–6.
59. Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology. 2000;54:1726–33.
60. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New Engl J Med. 2011;365:1293–303.
61. Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–56.
62. Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20:705–16.
63. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New Engl J Med. 2012;367:1098–107.
64. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New Engl J Med. 2012;367:1087–97.
65. Baum K, O’Leary C, Coret Ferrer F, et al. Comparison of injection site pain and injection site reactions in relapsing–remitting multiple sclerosis patients treated with interferon beta-1a or 1b. Mult Scler. 2007;13:1153–60.
66. Harris C, Billisberger K, Tillotson L, et al. Injection-site pain in patients with multiple sclerosis: interferon beta-1b versus interferon beta-1a. Int J MS Care. 2005/2006;7:132–6.
67. Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23:453–62.
68. Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138.
69. Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19:S24–40.
70. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551–4.
71. Jokubaitis VG, Spelman T, Lechner-Scott J, et al. The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PLoS One. 2013;8:e59694.
72. Kozubski W. Autoinjector improves injection-related tolerability issues in patients with multiple sclerosis––exploring the new ExtaviJect™ 30G system for the injection of interferon beta-1b. Eur Neurol Rev. 2010;5:77–81.
73. Pozzilli C, Schweikert B, Ecari U, Oentrich W. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis––results of the betaPlus observational cohort study. J Neurol Sci. 2011;307:120–6.
74. Gobbi C, Meier DS, Cotton F, et al. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol. 2013;13:101.